Study Objective: To compare sleep characteristics, rapid eye movement (REM) sleep without atonia, and REM sleep behavior disorder (RBD) in patients with progressive supranuclear palsy (tauopathy), patients with Parkinson's disease (a synucleinopathy), and control subjects. Design: Sleep interview, overnight polysomnography, and Multiple Sleep Latency Tests. Patients: Forty-five age-and sex-matched patients with probable progressive supranuclear palsy, (n = 15, aged 68 ± 8 years, 7 men), patients with Parkinson disease (n = 15), and control subjects (n = 15). Settings: Tertiary-care academic hospital. Intervention: N/A. Results: Compared to the 2 other groups, patients with progressive supranuclear palsy had a longer duration of wakefulness after sleep onset and twice as much sleep fragmentation and percentage of stage 1 sleep but had similar apnea-hypopnea indexes, periodic leg movements indexes, and mean daytime sleep latencies. REM sleep percentage was as low in patients with progressive supranuclear palsy (8% ± 6% of total sleep time) as in patients with Parkinson disease (10% ± 4%), versus 20% ± 6% in controls (analysis of variance, P < .0001). Interestingly, patients with progressive supranuclear palsy had percentages of REM sleep without atonia (chin muscle activity: 33% ± 36% of REM sleep) similar to those of patients with Parkinson disease (28% ± 35%) and dramatically higher than those of controls (0.5% ± 1%, analysis of variance, P =.008). Four (27%) patients with progressive supranuclear palsy had more than 50% REM sleep without atonia (as did a similar number of patients with Parkinson disease), and 2 of them (13%, vs 20% of patients with Parkinson disease) had clinical RBD. The four patients with progressive supranuclear palsy with excessive daytime sleepiness slept longer at night than the 11 patients with progressive supranuclear palsy who were alert (442 ± 14 minutes vs 312 ± 74 minutes, student t tests, P = .004), suggesting a primary nonnarcoleptic hypersomnia. Conclusion: REM sleep without atonia and RBD were as frequent in patients with progressive supranuclear palsy as in patients with Parkinson disease. It suggests that the downstream cause of parkinsonism, rather than its primary neuropathology (synucleinopathy vs tauopathy), is a key factor for REM sleep behavior disorder. 
INTRODUCTION

RAPID EYE MOVEMENT (REM) SLEEP BEHAVIOR DISOR-DER (RBD), A DISABLING PARASOMNIA THAT INCLUDES ENACTED DREAMS AND REM SLEEP WITHOUT ATONIA,
affects one third of patients with Parkinson disease (PD). 2 RBD is even more common (80%-90%) in patients with multiple system atrophy and dementia with Lewy body disease, 3,4 2 other neurodegenerative diseases characterized on postmortem examination, as is PD, by deposit of alpha-synuclein protein in the brain neurons. 5 In addition, as many as one third to two thirds of patients with a diagnosis of idiopathic RBD may, in the subsequent decade after diagnosis, develop signs of parkinsonism. 6, 7 Lewy bodies have been found within the brain of a single patient presenting with no signs other than 'idiopathic' RBD. 8 In contrast, RBD was reported to be rare in a series of patients with Alzheimer disease, progressive supranuclear palsy (PSP), frontotemporal dementia, and corticobasal degeneration. 4 These 4 neurodegenerative diseases are characterized by tau-protein deposit in neurons. It has been suggested that RBD is a marker of synucleinopathy rather than of tauopathy and could be used as an additional diagnostic criteria to discriminate, in a patient with progressive cognitive impairment, a case of Lewy body disease rather than of Alzheimer disease. 9 PSP, also known eponymously as Steele-RichardsonOlszewski syndrome, is a rare disease that affects 6.5 per 100 000 subjects, 10 a prevalence 200 times lower than PD. Patients with PSP show a complex range of symptoms, including paralysis of vertical gaze, postural instability and falls, 11 frontal cognitive impairment, dysarthria and dysphagia, parkinsonism, and dystonic rigidity of neck and upper trunk. 12 Unlike those of PD, PSP motor symptoms are poorly levodopa responsive. The disease is progressive, and patients die from pulmonary embolism or aspiration pneumonia after a median of 7 years. Most patients with PSP complain of insomnia. Polysomnographic studies have reported reduced total sleep time and increased sleep fragmentation early in the course of the disease. With the progression of the disease, REM sleep is dramatically reduced. [13] [14] [15] [16] [17] [18] The velocity of REMs may be reduced with occasional square-wave jerks, both during wakefulness and during REM sleep. Despite these extensive sleep studies in PSP, a specific study of RBD and its polygraphic correlates-REM sleep without atonia (RWA)-has been performed in only 2 patients, in whom it was normal. 9 Furthermore, although sleep abnormalities may impair daytime vigilance, there has been no systematic study reporting on excessive daytime sleepiness in patients with PSP. To determine if patients with PSP have RBD, RWA, and abnormal daytime sleepiness, we conducted a prospective study of nighttime sleep and daytime vigilance in 15 patients with PSP, 15 control subjects, and 15 patients with PD, all matched for sex and age.
METHODS
Subjects
Between February 2001 and February 2002, 23 patients with PSP were followed at the movement disorder clinics of 2 university hospitals. They were prospectively offered a sleep study. Two patients refused to take part, and 1 patient died before the sleep study. Five other patients completed the sleep study but their data were removed from the analysis because they were treated with antidepressant drugs, which could disturb the analysis of muscle tone during REM sleep. Finally, 15 patients, 8 women and 7 men, completed the study, which was approved by the local ethics committee. All patients met clinical diagnostic criteria for probable PSP, including parkinsonism, early occurrence of falls, saccade abnormalities on electrooculography, and levodopa responsiveness lower than 50% (their motor score on Unified Parkinson's Disease Rating Scale-part III [UPDRS-III] was decreased by less that 50% during a standardized acute levodopa challenge). 12 They were aged 68 ± 8 years (mean ± SD, range 55-80 years). The disease course ranged from 1 to 8 years, with a mean of 4 ± 2 years (Table 1) . They had a mild cognitive defect, as demonstrated by a Mini Mental State Examination score of 24 ± 5 (range 14-30). 19 They were severely disabled, with a mean 29 ± 14 (range motor score on the UPDRS-III while optimally treated, 20 a score that has also been validated in patients with PSP. 21 Nine patients were treated with levodopa, and 1 of them also received a dopamine agonist (ropinirole). Four patients took an evening dose of a benzodiazepine or benzodiazepine-related drug (clonazepam 0.2 mg/day, prescribed for alleviating RBD, bromazepam 1.5 mg/day, nitrazepam 5 mg/day, and zopiclone 7.5 mg/day). None of these 15 patients with PSP received antidepressant therapy.
We selected 15 age-and sex-matched patients with PD from a series of PD patients who had sleep interviews, overnight videopolysomnography, and Multiple Sleep Latency Tests in our program of the systematic study of sleep in patients with PD. Their demographic, clinical, and treatment characteristics are provided in Table 1 . They were treated with levodopa alone (7/15), ropinirole alone (1/15), and a combination of levodopa and a dopamine agonist (7/15: pergolide [2] ; bromocriptine: [2] ; ropinirole [3] ). In addition, 4 patients took a benzodiazepine or benzodiazepinerelated drug at bedtime (clonazepam 0.5 mg/day, flunitrazepam 1 mg, zopiclone 7.5 mg/day, zolpidem 20 mg/day). None of the patients took any antidepressant drugs.
We selected age-and sex-matched controls from a series of 104 subjects seen in the department of internal medicine who had a potential diagnosis of venous thromboembolism, not subsequently confirmed, who were systematically studied, after signed agreement, with a sleep interview and a polysomnogram within 1 month (Table 1) . They had no neurologic disease. Three subjects took a benzodiazepine at bedtime (lorazepam 0.5 mg, bromazepam 1.5 mg, oxazepam 25 mg), and none of them took any antidepressant drugs.
Study Design
Each patient was studied in the sleep laboratory for 24 hours. The protocol included (1) motor disability scale, 20 (2) interview of patient and caregiver about sleep disorders, (3) Mini Mental State Examination, 19 (4) Epworth Sleepiness Scale, 22 (5) class-II HLA phenotype (only in the PSP group), (6) nighttime sleep recordings from lights off (ad lib) to 6:30 AM (all patients woke up spontaneously before that time); and (7) 5 clinical Multiple Sleep Latency Tests. 23 The controls underwent only the sleep interview, the Mini Mental State Examination, and the nighttime recordings.
Nighttime polysomnographic recordings included frontocentral and occipitocentral bipolar electroencephalography, electrooculogram, chin and bilateral tibialis anterior surface electromyography (EMG; arriving through a Y montage to the same amplifier), nasal pressure cannulas, tracheal sounds through a microphone, thoracic and abdominal belts to measure respiratory movements, pulse rate, and oximetry (Cidelec Ltd, France). Patients were under the constant supervision of a sleep technologist, who monitored the recordings. The sleep stages, arousals, periodic leg movements, and respiratory events were scored visually according to standard criteria. 24, [25] [26] [27] The alpha rhythm was measured during an evening period of quiet wakefulness, on the occipitocentral lead, using fast Fourier transformation. Tonic muscle activity was quantified second per second during REM sleep on the chin EMG as a muscle activity with an amplitude at least equal to the amplitude observed during quiet wakefulness. It was then divided by the total duration of REM sleep to obtain the percentage of RWA. Leg muscle activity was measured second per second on the leg muscle EMG as a transient and frank elevation of muscle tone. The duration of leg muscle activity was also divided by total REM sleep to obtain the percentage of leg muscle activity during REM sleep. The EMG measures were performed both by scorers aware of the patient's diagnosis (IA, MMA) and by an independent scorer blinded to the diagnosis, with similar results. Statistics were performed using analyses of variance for comparison of continuous variables between the 3 groups. When the significance level (P < .05) was obtained, we performed posthoc analysis using Bonferroni corrected t tests, at the significance level of P < .01. Unpaired t tests were performed for comparisons limited to the PSP and PD groups or for intragroup comparisons. Results are reported as mean ± SD, except for the daytime mean sleep latencies (mean ± SEM).
RESULTS
Clinical Interview
As expected by matching, age and sex of the patients were identical between groups. Body mass index was not different between groups. Although PSP patients had a shorter disease course than PD patients, they were as equally motor disabled, more cognitively impaired, and received lower daily levodopa-equivalents doses (Table 1) . Six PSP patients, 5 PD patients, and 6 control subjects complained of difficulties initiating or maintaining sleep. Two PSP patients, 2 PD patients, and 2 control subjects met the clinical criteria of restless legs syndrome. Clinical RBD was reported by 2 men (13% of the group) with PSP, 3 men (20%) with PD, and no controls. The Epworth Sleepiness Scale score was not different between groups (Table 1) . Two PSP patients, 2 PD patients, and 3 controls had an Epworth Sleepiness Scale score greater than 10.
Nighttime Sleep
Nighttime sleep measures are shown in Table 2 . Electroencephalographic abnormalities were found only in PSP patients. Alpha rhythm was slower than 8 Hz during the waking electroencephalogram in 4 patients. Isolated frontal spikes were also observed in 4 patients, and although this was not formally quantified, spindles were rare. The alpha rhythm during wakefulness was slower in PSP patients than in controls, but the difference did not reach significance when compared with PD patients (Table 2) .
Total sleep time was less than 300 minutes in 7 PSP patients, in 6 PD patients and in 0 controls but was not significantly different between groups. PSP patients tended to have lower sleep efficiency and a had longer duration of wakefulness after sleep onset, longer REM sleep latency, higher percentage of stage 1 sleep, and almost twice as great an arousal index as the PD patients and controls. REM sleep percentage was lower in PSP and PD patients than in controls. There were no differences in apnea-hypopnea indexes between the 3 groups. The apneahypopnea index was greater than 15 in 9 (60%) PSP patients, in 9 (60%) PD patients, and in 6 (40%) controls (no significant difference in frequencies).
Motor Activity During Sleep
The mean percentages of RWA were higher in PSP patients and in PD patients than in controls (Table 2 ). In 4 PSP patients (27% of the group; 2 men, 2 women,) and 4 PD patients (27% of the group; 2 men, 2 women), RWA represented more than 50% of REM sleep duration, while this was never observed in the controls The P value is derived from the analysis of variance between the 3 conditions: *Progressive supranuclear palsy (PSP) group different from both Parkinson disease (PD) and control groups; † PSP and PD groups different from control group; ‡ PSP group different from control group; § PSP group different from PD group. REM refers to rapid eye movement (Figure 1 ). The percentage of leg EMG activity during REM sleep was not different between the 3 groups. The 4 PSP patients with RWA had an alpha rhythm (8.2 ± 1.3 Hz) that was not different from that of the 11 PSP patients without RWA (9.1 ± 1.6 Hz, P = .38). This was also the case for the PD patients with RWA (n = 4, alpha rhythm: 9.5 ± 1.0 Hz) and without RWA (n = 11, alpha rhythm: 10.3 ± 2.4 Hz, P = .60). The indexes of periodic leg movements during sleep were not significantly different between the 3 groups. Seven PSP patients had more than 25 periodic leg movements per hour of sleep, versus 5 PD patients and 2 controls.
Daytime Sleepiness
During Multiple Sleep Latency Tests, the mean sleep latency was not different between PSP and PD patients. Four PSP patients and 1 PD patient had an abnormal (< 8 minutes 28 ) mean sleep latency. These 4 PSP patients had arousal indexes similar to those of the 11 PSP patients with normal daytime mean sleep latencies (40.4 ± 21.6 vs 48.8 ± 31.3, P = .69) but slept longer during the night (total sleep time: 442 ± 14 minutes vs 312 ± 74 minutes, P = .004). Except for 1 isolated sleep-onset REM period observed in a PSP patient, no narcolepsy-like pattern [ie, 2 or more sleep-onset REM periods among 5 latency tests] was found in PSP or PD patients. In the PSP group, the HLA-class II allele was DQB1-0201 in 4 of 30 (13%) alleles, DQB1-03 (0301, 0302, 0307, 0309) in 8 of 30 (27%) alleles, DQB1-0501 in 5 of 30 (17%) alleles, and DQB1-0602 in 3 of 30 (10%) alleles. These percentages were not different from those found in French controls. 29 
DISCUSSION
The main finding is that 27% of patients with PSP, a tauopathy with parkinsonism, had a large percentage of RWA and 13% had RBD. These frequencies were similar to those of age-and sexmatched patients with PD, a synucleinopathy, while RBD and RWA were not found in controls. Furthermore, although PSP patients had a more fragmented sleep, they were as sleepy during the day as PD patients, but neither had a narcolepsy-like phenotype.
Boeve et al have suggested that RBD is a hallmark of synucleinopathies, since it is very rare in tauopathies. 9 However, only 2 patients with PSP were interviewed and recorded in that series. Our results challenge this hypothesis and demonstrate that RBD and RWA may affect as many as one third of patients with PSP and should not preclude this diagnosis.
There are several limitations to our findings. We did not record arm movements or the video images. This limited the opportunity to record speech and hands movements, which are frequently found in patients with RBD. Interestingly, the patients with PSP had percentages of tonic EMG activity during REM sleep similar to those of matched PD patients. The 60% to 100% RWA in our PSP and PD patients resemble the more than 50% RWA observed in one third of PD patients recorded by Gagnon et al. 2 The abnormal muscle activity was mainly observed on the chin muscle, however, since PSP had the same small amount of leg muscle activity that patients from the other groups had. Again, the arm muscles were not recorded, preventing further interpretation of phasic muscle activity during REM sleep.
Our PSP patients had low amounts of REM sleep, which is a common abnormality in PSP, but this reduction of REM sleep was not different from that of matched PD patients. This is probably because our PSP patients had a mean 4-year disease duration, allowing the observation of sufficient REM sleep amounts to measure the level of atonia. We think that the selection of PD patients of the same age, but with longer disease duration and similar motor disability, provides a more adequate parkinsonian control group than adjustment of disease durations because PD patients are as disabled during the night as PSP patients, thereby allowing comparison of sleep measures not biased by impaired nocturnal mobility. As REM sleep progressively disappears with the rapid course of the disease, it is probable that RBD disappears too, thereby explaining why RBD has not been previously reported in patients with advanced PSP.
The observation of RBD and RWA in PSP patients raises the question of RBD in other tauopathies. Large series of patients with Alzheimer disease have been recorded during the night, but sleep has rarely been studied in frontotemporal dementia and in corticobasal degeneration. Evidence is accumulating that symptomatic RBD can be observed in various neurodegenerative diseases, whatever the nature of the lesions. Indeed, patients with spinocerebellar ataxia, a polyglutamine disease, may have RBD and RWA, whether they had spinocerebellar ataxia type 3/Machado-Joseph disease 30, 31 or spinocerebellar ataxia type 1 or 2. 32 Patients with the parkin mutation, a mutation that leads to early-onset parkinsonism without intraneuronal alpha-synuclein deposits, can also exhibit RBD and RWA. 33 This suggests that it is the location of the lesion, rather than the type of lesion, that is important in the genesis of RBD. PSP, synucleinopathies, and spinocerebellar ataxia are diseases characterized by brain, especially brainstem, neuronal death. All 3 diseases involve, to various degrees, the dopaminergic system. None is limited to that system, however, thereby precluding further attempts to localize the lesions responsible for RBD. The cholinergic system may also be involved. In animal studies, it has been shown that REMsleep executive cholinergic and cholinoceptive neurons, located in the pedunculopontine tegmentum (locus coeruleus alpha and perialpha in the cat), are inhibited by monoaminergic (serotonin, histamine, norepinephrine, known to be preserved in PSP) and hypothalamic hypocretinergic descending systems and activated by cholinergic descending systems. 34 In PSP, the severe loss of cholinergic neurons previously observed in the pedunculopontine tegmentum 35 may progressively and directly affect the REMsleep executive and activating systems. This would explain the abnormalities in both duration and quality (ie, absence of normal atonia) of REM sleep in our patients with PSP.
We found that 27% of PSP patients had an abnormal mean daytime sleep latency. Previous measures of Multiple Sleep Latency Tests have been performed, to the best of our knowledge, in only 3 patients with PSP. 18 There has been increased concern about people with PD having excessive daytime sleepiness and potential motor vehicle accidents when driving. 36 Since PSP patients are disabled earlier and more severely than PD patients, one would imagine that they would stop driving earlier and be less affected by excessive daytime sleepiness when activities of daily living are also limited. This assertion should, however, be determined in individual cases, at least at the beginning of the disease. In our study, patients with excessive daytime sleepiness had similar sleep fragmentation but longer nocturnal sleep than those with normal alertness, suggesting that sleepiness was caused by a primary central hypersomnia. The number of patients is limited here, however, preventing further speculations. Excessive daytime sleepiness was as severe as in our patients with PD, but the narcolepsy-like pattern that has been reported in PD patients was not observed here. 37 Our data suggest that the mechanism underlying excessive daytime sleepiness differs in PD and in PSP. REM-sleep executive systems may be too damaged to produce sleep onset in REM periods during daytime naps. On the other hand, since 60% of our patients with PSP had an obstructive apnea-hypopnea index greater than 15, excessive daytime sleepiness may be partly caused by sleep-disordered breathing. This has not been previously reported, possibly because nocturnal respiratory events have not been monitored or were monitored with methods (oximetry 38 or naso-oral thermistance 17 ) now known to produce false-negative results. 27 The prevalence of sleep apnea was not different, however, between age-and sex-matched PD patients and controls, suggesting, rather, that sleep apnea reflects common risk factors such as aging and male sex. The possibility of sleep apnea in PSP patients should, however, be kept in mind by neurologists before they prescribe drugs that may promote sleep apnea, such as benzodiazepines, or apnea-promoting position, such as the supine sleep position.
CONCLUSION
The definitive observation of RBD and RWA in PSP patients, at the same frequency as in PD patients, suggests that RBD is not limited to synucleinopathies but also affects at least 1 type of tauopathy with parkinsonism. Our observation also suggests that RBD is dependent on the site of the lesion rather than on the type of pathologic neuronal inclusions. In addition, some patients suffer from excessive daytime sleepiness that may be caused by a primary PSP-related hypersomnia. 
PROVIGIL-the first and only wake-promoting agent-is indicated to improve wakefulness in patients with
PROVIGIL ( m o d a f i n i l ) TABLETS [C-IV]
CPAP Use in Patients with OSAHS:
In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. General: Patients should be cautioned about operating an automobile or other hazardous machinery until they are reasonably certain that PROVIGIL therapy will not adversely affect their ability to engage in such activities.
Patients Using Contraceptives:
The effectiveness of steroidal contraceptives may be reduced when used with PROVIGIL and for 1 month after discontinuation. Alternative or concomitant methods of contraception are recommended during and for 1 month after discontinuation of PROVIGIL. Cardiovascular System: In clinical studies of PROVIGIL, signs and symptoms including chest pain, palpitations, dyspnea and transient ischemic T-wave changes on ECG were observed in three subjects in association with mitral valve prolapse or left ventricular hypertrophy. It is recommended that PROVIGIL tablets not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. Such signs may include but are not limited to ischemic ECG changes, chest pain, or arrhythmia.
Patients with a recent history of MI or unstable angina should be treated with caution. Blood pressure monitoring in short-term controlled trials showed no clinically significant changes in mean systolic and diastolic blood pressure in patients receiving PROVIGIL as compared to placebo. However, a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). The differential use was slightly larger when only studies in OSAHS were included, with 3.4% of patients on PROVIGIL and 1.1% of patients on placebo requiring such alterations in the use of antihypertensive medication. Increased monitoring of blood pressure may be appropriate in patients on PROVIGIL. Central Nervous System: There have been reports of psychotic episodes associated with PROVIGIL use. One healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of PROVIGIL and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation. Caution should be exercised when PROVIGIL is given to patients with a history of psychosis.
Patients with Severe Renal Impairment: Treatment with PROVIGIL resulted in much higher exposure to its inactive metabolite, modafinil acid, but not PROVIGIL itself.
Patients with Severe Hepatic Impairment: PROVIGIL should be administered at a reduced dose because its clearance is decreased. Elderly Patients: Elderly patients may have diminished renal and/or hepatic function; therefore, dosage reduction should be considered.
Information for Patients:
Physicians are advised to discuss the following with patients taking PROVIGIL. PROVIGIL is indicated for patients who have abnormal levels of sleepiness. PROVIGIL has been shown to improve, but not eliminate this abnormal tendency to fall asleep. Therefore, patients should not alter their previous behavior with regard to potentially dangerous activities (eg, driving, operating machinery) or other activities requiring appropriate levels of wakefulness, until and unless treatment with PROVIGIL has been shown to produce levels of wakefulness that permit such activities. Patients should be advised that PROVIGIL is not a replacement for sleep.
Patients should be informed that it may be critical that they continue to take their previously prescribed treatments (eg, patients with OSAHS receiving CPAP should continue to do so).
Patients should be informed of the availability of a patient information leaflet, and they should be instructed to read the leaflet prior to taking PROVIGIL. Pregnancy: Patients should notify their physician if they become pregnant or intend to become pregnant during therapy. They should be cautioned of the potential increased risk of pregnancy when using steroidal contraceptives (including depot or implantable contraceptives) with PROVIGIL and for 1 month after discontinuation of therapy. In the drug interaction study between PROVIGIL and ethinyl estradiol (EE 2 ), on the same days as those for the plasma sampling for EE 2 pharmacokinetics, a single dose of triazolam 0.125 mg was also administered. Mean C max and AUC 0-' of triazolam were decreased by 42% and 59%, respectively, and its elimination half-life was decreased by approximately an hour after the modafinil treatment. In the absence of interaction studies with monoamine oxidase (MOA) inhibitors, caution should be exercised. Other Drugs: No significant changes in the pharmacokinetics of warfarin occurred in healthy subjects given 1 dose of warfarin 5 mg following chronic administration of PROVIGIL. However, more frequent monitoring of prothrombin times/INR is advised when PROVIGIL is coadministered with warfarin. PROVIGIL once daily 200 mg/day for 7 days followed by 400 mg/day for 21 days decreased ethinyl estradiol C max and AUC 0-24 by a mean 11% and 18% with no apparent change in the elimination rate. One interaction between PROVIGIL and cyclosporine has been reported in a 41-year-old female. After 1 month of PROVIGIL 200 mg/day, cyclosporine blood levels decreased by 50%. Dosage adjustment for cyclosporine may be needed. Potential Interactions with Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P-450 Isoenzymes and Other Hepatic Enzymes: In primary human hepatocytes, PROVIGIL slightly induced CYP1A2, CYP2B6 and CYP3A4 in a dose-dependent manner. In vitro experiments do not necessarily predict response in vivo; caution should be exercised when PROVIGIL is coadministered with drugs that are metabolized by enzymes. In human hepatocytes, PROVIGIL produced a dose-related suppression of CYP2C9 activity suggesting a potential for metabolic interaction between PROVIGIL and substrates of this enzyme (eg, S-warfarin and phenytoin). In healthy volunteers, chronic PROVIGIL treatment had no significant effect on single-dose pharmacokinetics of warfarin vs placebo. In human liver microsomes, PROVIGIL and modafinil sulfone reversibly inhibited CYP2C19. Both compounds combined could produce sustained partial enzyme inhibition. Drugs largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination with PROVIGIL coadministration and may require dose reduction and monitoring for toxicity. CYP2C19 provides ancillary metabolism of some tricyclic antidepressants (eg, clomipramine and desipramine) primarily metabolized by CYP2D6. In tricyclic users deficient in CYP2D6, CYP2C19 metabolism may be substantially increased. PROVIGIL may elevate tricyclics in this patient subset. A reduction in tricyclic dose may be needed. Due to partial involvement of CYP3A4 elimination of PROVIGIL, coadministration of potent inducers of CYP3A4 (eg, carbamazepine, phenobarbital, rifampin) or inhibitors of CYP3A4 (eg, ketoconazole, itraconazole) could alter modafinil plasma levels. Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis: The highest dose studied in carcinogenesis studies represent 1.5 times (mouse) or 3 times (rat) the maximum human daily dose of 200 mg on a mg/m 2 basis. There was no evidence of tumorigenesis associated with PROVIGIL administration in these studies, but because the mouse study used an inadequate high dose below that representative of a maximum tolerated dose, the carcinogenic potential in that species has not been fully evaluated.
Mutagenesis:
There was no evidence of mutagenic or clastogenic potential of PROVIGIL. Impairment of Fertility: PROVIGIL was administered orally to male and female rats prior to and throughout mating and gestation at up to 23 times the recommended human dose of 200 mg/day on a mg/m 2 basis with no effect on fertility. Pregnancy: Pregnancy Category C: PROVIGIL administered orally to pregnant rats throughout the period of organogenesis caused, in the absence of maternal toxicity, an increase in resorptions and an increased incidence of hydronephrosis and skeletal variations in the offspring at a dose of 200 mg/kg/day (10 times the recommended human dose of 200 mg/day on a mg/m 2 basis) but not at 100 mg/kg/day. However, in a subsequent study of up to 480 mg/kg/day (23 times the recommended human dose on a mg/m 2 basis), which included maternally toxic doses, no adverse effects on embryofetal development were seen. PROVIGIL administered orally to pregnant rabbits throughout the period of organogenesis at doses up to 100 mg/kg/day (10 times the recommended human dose on a mg/m 2 basis) had no effects on embryofetal development. However, in a subsequent study in pregnant rabbits, increased resorptions, and increased alterations in fetuses from a single litter (open eye lids, fused digits, rotated limbs), were observed at 180 mg/kg/day (17 times the recommended human dose on a mg/m 2 basis), a dose that was also maternally toxic. PROVIGIL administered orally to rats throughout gestation and lactation at doses up to 200 mg/kg/day (5 times the recommended human dose on a mg/m 2 basis), had no effects on the postnatal development of the offspring. There are no adequate and well-controlled studies in pregnant women. PROVIGIL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery: The effect of PROVIGIL on labor and delivery in humans has not been systematically investigated. Nursing Mothers: It is not known whether PROVIGIL or its metabolites are excreted in human milk. Caution should be exercised when PROVIGIL is administered to a nursing woman. PEDIATRIC USE: Safety and effectiveness in individuals below 16 years of age have not been established. Leukopenia has been reported in pediatric patients taking PROVIGIL. GERIATRIC USE: Safety and effectiveness in individuals above 65 years of age have not been established. ADVERSE REACTIONS: PROVIGIL has been evaluated for safety in over 3500 patients, of whom more than 2000 patients with excessive sleepiness associated with primary disorders of sleep and wakefulness were given at least 1 dose of PROVIGIL. In clinical trials, PROVIGIL has been found to be generally well tolerated and most adverse experiences were mild to moderate. The most commonly observed adverse events (*5%) associated with the use of PROVIGIL more frequently than placebo-treated patients in the placebo-controlled clinical studies in primary disorders of sleep and wakefulness were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia.
In the placebo-controlled clinical trials, 8% of the 934 patients who received PROVIGIL discontinued due to an adverse experience. The most frequent reasons for discontinuation that occurred at a higher rate for PROVIGIL than placebo patients were headache (2%), nausea, anxiety, dizziness, insomnia, chest pain, and nervousness (each <1%).
The incidence of adverse experiences that occurred at a rate of *1% and were more frequent in patients treated with PROVIGIL than in placebo patients in the principal trials are listed below. Consult full prescribing information on adverse events.
